Jasper Therapeutics, Inc. - Class A Common Stock (JSPR)
6.0600
-0.6400 (-9.55%)
Jasper Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapeutics to address critical unmet medical needs, particularly in the fields of hematology and oncology
The company is committed to advancing transformative therapies that enhance patient outcomes and improve the quality of life through cutting-edge research and development. Jasper Therapeutics leverages its proprietary technologies and expertise to create novel treatments that aim to tackle complex diseases, fostering collaborations to expedite the delivery of its breakthroughs to patients in need.
Jasper Therapeutics' SPOTLIGHT study reports 93% clinical response in cold urticaria and symptomatic dermographism. The 120mg dose showed 83% complete response and no severe adverse events. Full data expected by mid-2025.
The Dow Jones closed higher by around 100 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Gainers HeartCore Enterprises, Inc. (NASDAQHTCR) jumped 119.6% to $1.96 in pre-market trading. HeartCore forged an agreement with rYojbaba Inc for its tenth Go IPO consulting service win.
